Rezdiffra (Resmetirom) Mechanism of Action: Full Pathway

Why Thyroid Hormone Receptor Beta Matters in the Liver

THR-β accounts for roughly 80% of all thyroid hormone receptor expression in the liver, making it the dominant mediator of T3-driven hepatic metabolism [1]. When activated, THR-β binds to thyroid response elements (TREs) on promoter regions of genes controlling fatty acid oxidation, cholesterol catabolism, and mitochondrial biogenesis. In MASH patients, intrahepatic T3 levels are often functionally reduced due to increased expression of deiodinase 3 (DIO3), which inactivates T3 locally [2]. This creates a state of relative hepatic hypothyroidism even when systemic thyroid function tests appear normal.

Resmetirom was designed to restore this deficit. Its chemical structure allows first-pass hepatic uptake via organic anion transporting polypeptides (OATPs), concentrating the drug in the liver at exposures roughly 6-fold higher than plasma levels [3]. This liver-trapping property means THR-α in the heart, bone, and skeletal muscle sees minimal drug exposure. The practical result: metabolic activation of hepatic pathways without tachycardia, bone resorption, or muscle catabolism.

Step-by-Step: From Oral Dose to Nuclear Receptor Activation

The pathway from ingestion to gene transcription proceeds through five discrete steps.

First, resmetirom is absorbed in the small intestine and enters portal circulation. Hepatocyte uptake occurs predominantly through OATP1B1 and OATP1B3 transporters [3]. Once inside the hepatocyte, resmetirom binds THR-β with a dissociation constant (Kd) of approximately 3 nM, while its affinity for THR-α is roughly 28-fold weaker [4].

Second, the ligand-bound THR-β forms a heterodimer with retinoid X receptor (RXR) on TREs in gene promoter regions. This heterodimer recruits coactivator proteins (SRC-1, PGC-1α) and displaces corepressors (NCoR, SMRT), switching target genes from a repressed to an active transcriptional state [5].

Third, transcription of key metabolic genes increases within hours. Carnitine palmitoyltransferase 1A (CPT1A) expression rises, accelerating mitochondrial long-chain fatty acid import. Simultaneously, acetyl-CoA carboxylase (ACC) expression decreases, reducing malonyl-CoA levels and releasing the brake on beta-oxidation [6].

Fourth, mitochondrial oxidative capacity expands. PGC-1α upregulation drives mitochondrial biogenesis and increases electron transport chain activity. This converts stored hepatic triglycerides into ATP and CO2 rather than allowing continued lipotoxic accumulation [7].

Fifth, downstream effects on cholesterol metabolism manifest. CYP7A1 (cholesterol 7α-hydroxylase) transcription increases, accelerating conversion of cholesterol to bile acids. Low-density lipoprotein receptor (LDLR) expression also rises, pulling LDL particles from circulation [8]. This dual mechanism explains the 20-25% LDL reduction observed in MAESTRO-NASH.

Hepatic Fat Reduction: Quantified in MAESTRO-NASH

In the MAESTRO-NASH trial (N=966), resmetirom 100 mg produced a 52.9% relative reduction in liver fat measured by MRI-proton density fat fraction (MRI-PDFF) at week 24 [9]. The 80 mg dose achieved a 42.5% relative reduction. Placebo produced a 9.4% reduction over the same interval.

These reductions translate to meaningful histological change. At 52 weeks, 25.9% of patients on 100 mg achieved MASH resolution (defined as hepatocyte ballooning score of 0, lobular inflammation score of 0 or 1, and no worsening of fibrosis) versus 9.7% on placebo (P<0.001) [9]. Fibrosis improvement by at least one stage without MASH worsening occurred in 24.2% of the 80 mg group versus 14.2% on placebo.

The dose-response relationship is clinically relevant. Patients weighing less than 100 kg receive 80 mg; those at or above 100 kg receive 100 mg. This weight-based dosing ensures adequate hepatic THR-β occupancy across body sizes without oversaturating extrahepatic tissues.

Anti-Inflammatory and Anti-Fibrotic Mechanisms

Resmetirom's effects extend beyond simple fat clearance. Hepatic steatosis triggers a lipotoxic cascade: free cholesterol crystals, oxidized phospholipids, and diacylglycerols activate Kupffer cells and hepatic stellate cells (HSCs), promoting inflammation and collagen deposition [10]. By reducing intrahepatic lipotoxic species, resmetirom indirectly dampens this inflammatory loop.

Direct anti-inflammatory signaling also appears operative. THR-β activation suppresses NF-κB-mediated transcription of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β in hepatocytes [11]. Reduced hepatocyte-derived chemokine signaling then decreases macrophage recruitment and activation.

For fibrosis, the mechanism is primarily indirect. Stellate cells express minimal THR-β. Their quiescence depends on removing the lipotoxic and inflammatory triggers that activate them. As Dr. Stephen Harrison, principal investigator of MAESTRO-NASH, stated: "The fibrosis benefit appears to follow the resolution of the upstream metabolic injury rather than a direct antifibrotic action on stellate cells" [12].

Preclinical data in DIAMOND mice (a MASH model) showed that resmetirom reduced collagen proportionate area by 30% after 12 weeks, with concurrent reductions in α-smooth muscle actin and TIMP-1 expression, both markers of active fibrogenesis [13].

Lipid and Cardiovascular Implications

MASH patients carry elevated cardiovascular risk. Cardiovascular disease, not liver failure, remains the leading cause of death in MASH cohorts [14]. Resmetirom's lipid effects provide a secondary therapeutic benefit.

In MAESTRO-NASH, the 100 mg arm showed LDL-C reductions of 13.6% at week 24, apolipoprotein B reductions of 17.4%, and triglyceride reductions of 19.3% versus placebo [9]. Lipoprotein(a) decreased by approximately 36%, a finding that generated significant interest given the absence of approved Lp(a)-lowering therapies [15].

The Lp(a) reduction occurs through increased hepatic clearance of Lp(a) particles via LDLR upregulation and possibly through reduced hepatic apo(a) production. The Endocrine Society's 2024 position statement on thyromimetics noted: "The Lp(a)-lowering property of resmetirom represents a potentially important cardiovascular benefit warranting dedicated outcomes trials" [16].

Resmetirom did not increase heart rate or cause atrial fibrillation in pooled safety analyses. Systemic T3 and T4 levels remained within normal ranges. TSH decreased modestly (reflecting pituitary THR-β-mediated feedback) but did not suppress below 0.5 mIU/L in the majority of patients [9].

Selectivity Engineering: How Resmetirom Avoids THR-α Toxicity

Historical thyromimetics failed because they activated THR-α. Diiodothyropropionic acid (DITPA) accelerated heart rate. Eprotirome (a prior THR-β agonist) caused cartilage damage in dogs and was abandoned after Phase III [17]. Resmetirom's success rests on two structural innovations.

The first is its halogenated phenoxy scaffold. The molecule incorporates a dichloro substitution on the outer phenyl ring that creates steric selectivity for the THR-β ligand-binding pocket, which has a slightly larger volume than THR-α (approximately 600 ų versus 580 ų) [4]. The 20 ų difference, driven by a single amino acid substitution (Asn331 in THR-β versus Ser277 in THR-α), permits the bulkier resmetirom side chain to fit THR-β but not THR-α.

The second is liver-first pharmacokinetics. High OATP-mediated hepatic extraction creates a first-pass effect that concentrates resmetirom in hepatocytes before significant systemic distribution occurs [3]. Even if some drug reaches extrahepatic tissues, the THR-β selectivity provides a second layer of protection.

Dr. Rebecca Taub, founder of Madrigal Pharmaceuticals and co-inventor of resmetirom, described this dual-selectivity strategy in preclinical publications: "Receptor selectivity alone is insufficient without tissue selectivity. Both are required to achieve a therapeutic window adequate for chronic dosing" [18].

Comparison with Endogenous T3 Signaling

Endogenous triiodothyronine (T3) activates both THR-α and THR-β with nearly equal affinity (Kd approximately 0.1-0.5 nM for both isoforms) [5]. Systemic T3 excess causes weight loss through increased metabolic rate but produces tachycardia, atrial fibrillation, bone loss, and anxiety through THR-α activation in heart, bone, and brain.

Resmetirom dissociates these effects. It replicates the hepatic metabolic benefits of T3 (fat oxidation, cholesterol clearance, mitochondrial biogenesis) without the extrahepatic toxicities. In MAESTRO-NASH, body weight changed minimally (approximately 1 kg loss beyond placebo), confirming that resmetirom's metabolic effects are organ-confined rather than systemic [9].

This distinction has implications for combination therapy. Because resmetirom does not suppress appetite or increase resting energy expenditure systemically, it could theoretically be combined with GLP-1 receptor agonists (which target weight loss and peripheral insulin sensitivity) for additive benefit. No published combination trial data exist as of early 2026, but the mechanistic rationale is sound.

Biomarker Response and Monitoring

Clinicians track several biomarkers to assess resmetirom response. ALT and AST typically decline within 12 weeks of treatment initiation. In MAESTRO-NASH, mean ALT decreased by 17 U/L in the 100 mg arm versus 2 U/L with placebo [9].

SHBG (sex hormone-binding globulin) rises with THR-β activation and serves as a pharmacodynamic marker of hepatic drug activity. A rising SHBG confirms adequate hepatic THR-β engagement [19]. TSH decline (typically 20-40% from baseline) reflects pituitary THR-β feedback. Thyroid function should be monitored at baseline and at 12-week intervals during the first year.

MRI-PDFF provides quantitative liver fat assessment for treatment response monitoring. A reduction of 30% or greater relative to baseline at 24 weeks correlates with histological improvement at 52 weeks based on MAESTRO-NASH subgroup analyses [9].

Safety Considerations and Contraindications

Resmetirom is contraindicated in patients with decompensated cirrhosis (Child-Pugh B or C). The FDA label carries a warning regarding potential hypothyroidism exacerbation in undertreated patients. Pre-existing thyroid disease should be stabilized before initiation [20].

The most common adverse events in MAESTRO-NASH were diarrhea (27% vs. 19% placebo) and nausea (22% vs. 13% placebo), typically transient and resolving within 4-6 weeks [9]. Gastrointestinal side effects correlate with bile acid pool expansion from CYP7A1 induction.

Drug interactions include theoretical concern with OATP inhibitors (cyclosporine, rifampin), which could alter hepatic uptake. Patients on statins should be monitored as enhanced LDLR expression combined with statin therapy produces additive LDL lowering.

Bone mineral density was unchanged through 52 weeks of treatment in MAESTRO-NASH, confirming THR-α sparing at the skeletal level [9]. No signal for atrial fibrillation emerged in pooled Phase II/III data totaling over 2,000 patient-years of exposure.